U.S. FDA Slams Warning Letter On Dr. Reddy's For GMP Violations At Mexico API And Steroids Site
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - U.S. FDA issued a warning letter to India's Dr. Reddy's Laboratories Ltd. following investigations that detected adulterated APIs at its Cuernavaca, Mexico site. The regulatory agency noted "significant deviations" from current good manufactuirng practices at the site. The FDA probe centers around unvalidated analytical methods, deficiencies in handling out-of-specification investigations and parameters used to ensure cGMP compliance
You may also be interested in...
U.S. FDA Clears Mexico Site For Dr. Reddy’s As Company Nears Goal of $3 Billion In Sales
A slew of launches and growth in emerging markets will have to counter an increasingly tough U.S. market
U.S. FDA Issues Warning For Contamination At Cadila's India Site
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3
U.S. FDA Issues Warning For Contamination At Cadila's India Site
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3